Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECT Imaging of HER2 Using 99mTc-ADAPT6 and 99mTc-DARPinG3 in Breast Cancer
NCT05376644Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- May 2022
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Open-label, single-arm trial of [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 in breast cancer, sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: 99mTc-ADAPT6 uptake at 2 hours, 99mTc-ADAPT6 tumor-to-background ratio at 2 hours and 4 more. Started May 2022; status: completed.
02
Drugs
[99mTc]Tc-ADAPT6[99mTc]Tc-(HE)3-G3
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05376644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376644.